Evans R Fernández Pérez1, Jeffrey J Swigris2, Anna V Forssén3, Olga Tourin4, Joshua J Solomon2, Tristan J Huie2, Amy L Olson2, Kevin K Brown2. 1. Interstitial Lung Disease Program and Autoimmune Lung Center, National Jewish Health, Denver, CO. Electronic address: Fernandezevans@njhealth.org. 2. Interstitial Lung Disease Program and Autoimmune Lung Center, National Jewish Health, Denver, CO. 3. Division of Pulmonary and Critical Care Medicine, and the Department of Biostatistics and Bioinformatics, National Jewish Health, Denver, CO. 4. Calgary Medical Center, Calgary, AB, Canada.
Abstract
BACKGROUND: The cornerstone of hypersensitivity pneumonitis (HP) management is having patients avoid the inciting antigen (IA). Often, despite an exhaustive search, an IA cannot be found. The objective of this study was to examine whether identifying the IA impacts survival in patients with chronic HP. METHODS: We used the Kaplan-Meier method to display, and the log-rank test to compare, survival curves of patients with well-characterized chronic HP stratified on identification of an IA exposure. A Cox proportional hazards (PH) model was used to identify independent predictors in time-to-death analysis. RESULTS: Of 142 patients, 67 (47%) had an identified IA, and 75 (53%) had an unidentified IA. Compared with survivors, patients who died (n = 80, 56%) were older, more likely to have smoked, had lower total lung capacity % predicted and FVC % predicted, had higher severity of dyspnea, were more likely to have pulmonary fibrosis, and were less likely to have an identifiable IA. In a Cox PH model, the inability to identify an IA (hazard ratio [HR], 1.76; 95% CI, 1.01-3.07), older age (HR, 1.04; 95% CI, 1.01-1.07), the presences of pulmonary fibrosis (HR, 2.43; 95% CI, 1.36-4.35), a lower FVC% (HR, 1.36; 95% CI, 1.10-1.68), and a history of smoking (HR, 2.01; 95% C1, 1.15-3.50) were independent predictors of shorter survival. After adjusting for mean age, presence of fibrosis, mean FVC%, mean diffusing capacity of the lung for carbon monoxide (%), and history of smoking, survival was longer for patients with an identified IA exposure than those with an unidentified IA exposure (median, 8.75 years vs 4.88 years; P = .047). CONCLUSIONS: Among patients with chronic HP, when adjusting for a number of potentially influential predictors, including the presence of fibrosis, the inability to identify an IA was independently associated with shortened survival.
BACKGROUND: The cornerstone of hypersensitivitypneumonitis (HP) management is having patients avoid the inciting antigen (IA). Often, despite an exhaustive search, an IA cannot be found. The objective of this study was to examine whether identifying the IA impacts survival in patients with chronic HP. METHODS: We used the Kaplan-Meier method to display, and the log-rank test to compare, survival curves of patients with well-characterized chronic HP stratified on identification of an IA exposure. A Cox proportional hazards (PH) model was used to identify independent predictors in time-to-death analysis. RESULTS: Of 142 patients, 67 (47%) had an identified IA, and 75 (53%) had an unidentified IA. Compared with survivors, patients who died (n = 80, 56%) were older, more likely to have smoked, had lower total lung capacity % predicted and FVC % predicted, had higher severity of dyspnea, were more likely to have pulmonary fibrosis, and were less likely to have an identifiable IA. In a Cox PH model, the inability to identify an IA (hazard ratio [HR], 1.76; 95% CI, 1.01-3.07), older age (HR, 1.04; 95% CI, 1.01-1.07), the presences of pulmonary fibrosis (HR, 2.43; 95% CI, 1.36-4.35), a lower FVC% (HR, 1.36; 95% CI, 1.10-1.68), and a history of smoking (HR, 2.01; 95% C1, 1.15-3.50) were independent predictors of shorter survival. After adjusting for mean age, presence of fibrosis, mean FVC%, mean diffusing capacity of the lung for carbon monoxide (%), and history of smoking, survival was longer for patients with an identified IA exposure than those with an unidentified IA exposure (median, 8.75 years vs 4.88 years; P = .047). CONCLUSIONS: Among patients with chronic HP, when adjusting for a number of potentially influential predictors, including the presence of fibrosis, the inability to identify an IA was independently associated with shortened survival.
Authors: Jordan N Fink; Hector G Ortega; Herbert Y Reynolds; Yvon F Cormier; Leland L Fan; Teri J Franks; Kathleen Kreiss; Steven Kunkel; David Lynch; Santiago Quirce; Cecile Rose; Robert P Schleimer; Mark R Schuyler; Moises Selman; Douglas Trout; Yasuyuki Yoshizawa Journal: Am J Respir Crit Care Med Date: 2005-01-18 Impact factor: 21.405
Authors: Y Ohtsuka; M Munakata; K Tanimura; H Ukita; H Kusaka; Y Masaki; I Doi; M Ohe; M Amishima; Y Homma Journal: Intern Med Date: 1995-10 Impact factor: 1.271
Authors: Moises Selman; Annie Pardo; Lourdes Barrera; Andrea Estrada; Susan R Watson; Keith Wilson; Natasha Aziz; Naftali Kaminski; Albert Zlotnik Journal: Am J Respir Crit Care Med Date: 2005-09-15 Impact factor: 21.405
Authors: H Takizawa; M Suko; N Kobayashi; K Ohta; S Shoji; T Horiuchi; H Okudaira; T Miyamoto; J Shiga Journal: Int Arch Allergy Appl Immunol Date: 1989
Authors: Traci N Adams; Chad A Newton; Kiran Batra; Muhanned Abu-Hijleh; Tyonn Barbera; Jose Torrealba; Craig S Glazer Journal: Lung Date: 2018-06-29 Impact factor: 2.584
Authors: Haruhiko Furusawa; Jonathan H Cardwell; Tsukasa Okamoto; Avram D Walts; Iain R Konigsberg; Jonathan S Kurche; Tami J Bang; Marvin I Schwarz; Kevin K Brown; Jonathan A Kropski; Mauricio Rojas; Carlyne D Cool; Joyce S Lee; Paul J Wolters; Ivana V Yang; David A Schwartz Journal: Am J Respir Crit Care Med Date: 2020-11-15 Impact factor: 21.405
Authors: Christopher J Ryerson; Tamera J Corte; Joyce S Lee; Luca Richeldi; Simon L F Walsh; Jeffrey L Myers; Jürgen Behr; Vincent Cottin; Sonye K Danoff; Kevin R Flaherty; David J Lederer; David A Lynch; Fernando J Martinez; Ganesh Raghu; William D Travis; Zarir Udwadia; Athol U Wells; Harold R Collard Journal: Am J Respir Crit Care Med Date: 2017-11-15 Impact factor: 21.405
Authors: Margaret L Salisbury; Jeffrey L Myers; Elizabeth A Belloli; Ella A Kazerooni; Fernando J Martinez; Kevin R Flaherty Journal: Am J Respir Crit Care Med Date: 2017-09-15 Impact factor: 21.405
Authors: Gaëtane C Michaud; Colleen L Channick; Anica C Law; Jessica B McCannon; MaryEllen Antkowiak; Garth Garrison; David Sayah; Richard H Huynh; Anna K Brady; Rosemary Adamson; Hilary DuBrock; Praveen Akuthota; Chad Marion; Charles Dela Cruz; James A Town; Başak Çoruh; Carey C Thomson Journal: Ann Am Thorac Soc Date: 2016-07
Authors: Kelly Andrews; Manik C Ghosh; Andreas Schwingshackl; Gabriel Rapalo; Charlean Luellen; Christopher M Waters; Elizabeth A Fitzpatrick Journal: Am J Physiol Lung Cell Mol Physiol Date: 2015-12-30 Impact factor: 5.464
Authors: Julie Morisset; Kerri A Johannson; Eric Vittinghoff; Carlos Aravena; Brett M Elicker; Kirk D Jones; Charlene D Fell; Helene Manganas; Bruno-Pierre Dubé; Paul J Wolters; Harold R Collard; Christopher J Ryerson; Brett Ley Journal: Chest Date: 2016-11-03 Impact factor: 9.410